| Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters C Smit, S De Hoogd, RJM Brüggemann, CAJ Knibbe Expert opinion on drug metabolism & toxicology 14 (3), 275-285, 2018 | 187 | 2018 |
| Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties C Smit, MYM Peeters, JN van den Anker, CAJ Knibbe Clinical pharmacokinetics 59 (6), 659-669, 2020 | 73 | 2020 |
| Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals C Smit, RE Wasmann, SC Goulooze, MJ Wiezer, EPA van Dongen, ... British Journal of Clinical Pharmacology 86 (2), 303-317, 2020 | 44 | 2020 |
| Efficient synthesis and applications of peptides containing adenylylated tyrosine residues C Smit, J Blümer, MF Eerland, MF Albers, MP Müller, RS Goody, A Itzen, ... Angewandte Chemie International Edition 39 (50), 9200-9204, 2011 | 31 | 2011 |
| Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults RE Wasmann, C Smit, R Ter Heine, SE Koele, EPH van Dongen, ... Journal of Antimicrobial Chemotherapy 74 (4), 978-985, 2019 | 25 | 2019 |
| Implications for IV posaconazole dosing in the era of obesity RE Wasmann, C Smit, MH van Donselaar, EPA van Dongen, RMJ Wiezer, ... Journal of Antimicrobial Chemotherapy 75 (4), 1006-1013, 2020 | 23 | 2020 |
| Tobramycin clearance is best described by renal function estimates in obese and non-obese individuals: results of a prospective rich sampling pharmacokinetic study C Smit, RE Wasmann, MJ Wiezer, HPA van Dongen, JW Mouton, ... Pharmaceutical Research 36, 1-12, 2019 | 17 | 2019 |
| Fixed dosing of liposomal amphotericin B in morbidly obese individuals RE Wasmann, C Smit, EPH van Dongen, RMJ Wiezer, J Adler-Moore, ... Clinical Infectious Diseases 70 (10), 2213-2215, 2020 | 16 | 2020 |
| A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin: towards individualized dosing in obese patients C Smit, RE Wasmann, SC Goulooze, EJ Hazebroek, EPA Van Dongen, ... Clinical Pharmacokinetics 58, 1333-1343, 2019 | 16 | 2019 |
| Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged … C Smit, SC Goulooze, RJM Brüggemann, CM Sherwin, CAJ Knibbe The AAPS Journal 23 (3), 53, 2021 | 14 | 2021 |
| Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling D Hofmann, C Smit, S Sayasone, M Pfister, J Keiser Clinical and Translational Science 15 (3), 700-708, 2022 | 13 | 2022 |
| Ciprofloxacin pharmacokinetics after oral and intravenous administration in (morbidly) obese and non-obese individuals: a prospective clinical study KP van Rhee, C Smit, RE Wasmann, PD van der Linden, R Wiezer, ... Clinical Pharmacokinetics 61 (8), 1167-1175, 2022 | 10 | 2022 |
| Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys) function C Smit, AM van Schip, EPA van Dongen, RJM Brüggemann, ML Becker, ... Journal of Antimicrobial Chemotherapy 75 (11), 3286-3292, 2020 | 10 | 2020 |
| Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen C Smit, D Hofmann, S Sayasone, J Keiser, M Pfister Clinical pharmacokinetics, 1-10, 2022 | 7 | 2022 |
| Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates S Samiee-Zafarghandy, T van Donge, G Fusch, M Pfister, G Jacob, ... Archives of Disease in Childhood 107 (1), 86-91, 2022 | 5 | 2022 |
| Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study C Smit, K Wiertz-Arts, EMW van de Garde Journal of Comparative Effectiveness Research 7 (6), 561-567, 2018 | 5 | 2018 |
| Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modeling help us to understand why? C Smit, AGJ Engbers, S Samiee-Zafarghandy, T Van Donge, SHP Simons, ... Neonatology 120 (1), 81-89, 2023 | 4 | 2023 |
| Effiziente Synthese und Anwendung von Peptiden mit adenylylierten Tyrosinresten C Smit, J Blümer, MF Eerland, MF Albers, MP Müller, RS Goody, A Itzen, ... Angewandte Chemie 39 (123), 9367-9371, 2011 | 2 | 2011 |
| Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure C Smit, S Sen, E von Dach, A Karmime, P Lescuyer, D Tonoli, J Bielicki, ... Antibiotics 11 (9), 1190, 2022 | 1 | 2022 |
| Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Nonobese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study (vol 36, 112 … C Smit, RE Wasmann, MJ Wiezer, H van Dongen, JW Mouton, ... PHARMACEUTICAL RESEARCH 37 (2), 2020 | | 2020 |
